AngioDynamics, Inc. (NASDAQ:ANGO – Get Free Report) has earned a consensus rating of “Hold” from the five brokerages that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $19.50.
Several research firms have recently issued reports on ANGO. Canaccord Genuity Group upped their price objective on AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Wall Street Zen upgraded AngioDynamics from a “hold” rating to a “buy” rating in a research note on Saturday, August 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a report on Friday, July 17th. Zacks Research lowered shares of AngioDynamics from a “hold” rating to a “strong sell” rating in a research note on Thursday, July 16th. Finally, HC Wainwright raised their price objective on shares of AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th.
Get Our Latest Analysis on ANGO
AngioDynamics Trading Down 1.7%
AngioDynamics (NASDAQ:ANGO – Get Free Report) last issued its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.04. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The firm had revenue of $86.61 million during the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, analysts predict that AngioDynamics will post -0.25 earnings per share for the current fiscal year.
Insider Activity at AngioDynamics
In related news, SVP Warren Nighan, Jr. sold 23,370 shares of the stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total value of $344,006.40. Following the transaction, the senior vice president directly owned 64,745 shares of the company’s stock, valued at $953,046.40. This trade represents a 26.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 6.00% of the stock is owned by company insiders.
Hedge Funds Weigh In On AngioDynamics
Several large investors have recently bought and sold shares of ANGO. Farther Finance Advisors LLC grew its holdings in shares of AngioDynamics by 146.4% during the fourth quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 1,199 shares during the last quarter. Kemnay Advisory Services Inc. purchased a new stake in shares of AngioDynamics in the 4th quarter valued at about $27,000. State of Wyoming acquired a new stake in shares of AngioDynamics in the 2nd quarter valued at about $31,000. Legal & General Group Plc acquired a new stake in shares of AngioDynamics in the 2nd quarter valued at about $45,000. Finally, Russell Investments Group Ltd. grew its stake in AngioDynamics by 329.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock worth $47,000 after buying an additional 3,213 shares during the last quarter. Institutional investors and hedge funds own 89.43% of the company’s stock.
AngioDynamics Company Profile
AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.
In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.
Featured Stories
- Five stocks we like better than AngioDynamics
- Dutch Bros Sell-Off Creates a Growth Opportunity
- NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat
- Is Abercrombie & Fitch’s Hot Streak Just Getting Started?
- Medtronic’s Stars Are Aligning for a Price Recovery
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.
